Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) – Pipeline Review, H2 2016’, provides in depth analysis on Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1)

The report reviews Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects

The report assesses Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Incyte Corporation

Inflection Biosciences Limited

Jasco Pharmaceuticals, LLC.

Novartis AG

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC

2.7.11.1) Overview 6

Therapeutics Development 7

Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC

2.7.11.1) - Products under Development by Stage of Development 7

Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC

2.7.11.1) - Products under Development by Therapy Area 8

Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC

2.7.11.1) - Products under Development by Indication 9

Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC

2.7.11.1) - Pipeline Products Glance 10

Late Stage Products 10

Early Stage Products 11

Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC

2.7.11.1) - Products under Development by Companies 12

Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC

2.7.11.1) - Therapeutics Assessment 14

Assessment by Monotherapy/Combination Products 14

Assessment by Mechanism of Action 15

Assessment by Route of Administration 16

Assessment by Molecule Type 17

Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC

2.7.11.1) - Companies Involved in Therapeutics Development 18

Incyte Corporation 18

Inflection Biosciences Limited 19

Jasco Pharmaceuticals, LLC. 20

Novartis AG 21

Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC

2.7.11.1) - Drug Profiles 22

IBL-100 - Drug Profile 22

Product Description 22

Mechanism Of Action 22

R&D Progress 22

INCB-53914 - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

JP-11646 - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

LGB-321 - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

PIM-447 - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

Small Molecules to Inhibit Pim Kinase for Oncology - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC

2.7.11.1) - Dormant Projects 28

Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC

2.7.11.1) - Discontinued Products 30

Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC

2.7.11.1) - Featured News & Press Releases 31

Apr 04, 2014: Roswell Park to Present Findings on Jasco Pharmaceuticals’ Novel PIM Inhibitor at AACR 2014 31

Apr 01, 2013: Jasco Pharma To Present Data On PIM Inhibitor Program At AACR Annual Meeting 2013 32

Mar 31, 2011: Jasco Pharma To Present Data On Preclinical PIM Inhibitor Program At AACR Annual Meeting 32

Appendix 33

Methodology 33

Coverage 33

Secondary Research 33

Primary Research 33

Expert Panel Validation 33

Contact Us 33

Disclaimer 34

List of Tables

List of Tables

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Products under Development by Companies, H2 2016 13

Assessment by Monotherapy/Combination Products, H2 2016 14

Number of Products by Stage and Mechanism of Action, H2 2016 15

Number of Products by Stage and Route of Administration, H2 2016 16

Number of Products by Stage and Molecule Type, H2 2016 17

Pipeline by Incyte Corporation, H2 2016 18

Pipeline by Inflection Biosciences Limited, H2 2016 19

Pipeline by Jasco Pharmaceuticals, LLC., H2 2016 20

Pipeline by Novartis AG, H2 2016 21

Dormant Projects, H2 2016 28

Dormant Projects (Contd..1), H2 2016 29

Discontinued Products, H2 2016 30

List of Figures

List of Figures

Number of Products under Development for, H2 2016 7

Number of Products under Development by Top 10 Indication, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 11

Assessment by Monotherapy/Combination Products, H2 2016 14

Number of Products by Stage and Mechanism of Actions, H2 2016 15

Number of Products by Stage and Routes of Administration, H2 2016 16

Number of Products by Stage and Molecule Type, H2 2016 17

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports